Get the Stockscreener App
1.36
0.73%
-0.01
After Hours:
1.33
-0.03
-2.21%
Scinai Immunotherapeutics Ltd Adr stock is traded at $1.36, with a volume of 49,441.
It is down -0.73% in the last 24 hours and down -12.82% over the past month.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.
See More
Previous Close:
$1.37
Open:
$1.37
24h Volume:
49,441
Relative Volume:
0.05
Market Cap:
$1.36M
Revenue:
-
Net Income/Loss:
$-9.29M
P/E Ratio:
-0.2615
EPS:
-5.2
Net Cash Flow:
$-9.42M
1W Performance:
+0.37%
1M Performance:
-12.82%
6M Performance:
-30.61%
1Y Performance:
-64.21%
1-Day Range:
$1.32
$1.376
1-Week Range:
$1.32
$1.63
52-Week Range:
$1.20
$6.18
Scinai Immunotherapeutics Ltd Adr Stock (SCNI) Company Profile
Name
Scinai Immunotherapeutics Ltd Adr
Sector
Industry
Phone
972-8-9302529
Address
JERUSALEM BIOPARK, 2ND FLOOR, JERUSALEM
Compare SCNI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SCNI
Scinai Immunotherapeutics Ltd Adr
|
1.36 | 4.37M | 0 | -9.29M | -9.42M | -5.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Scinai Immunotherapeutics Ltd Adr Stock (SCNI) Latest News
Scinai receives $246,000 grant to expand biotech manufacturing By Investing.com - Investing.com South Africa
Scinai receives $246,000 grant to expand biotech manufacturing - Investing.com
Scinai Immunotherapeutics (NASDAQ: SCNI) Reports First-Half 2025 Results, Strengthened Cash Position - Barchart.com
Scinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance Sheet - Barchart.com
Scinai Immunotherapeutics (NASDAQ:SCNI) Trading Down 3.8% – Here’s What Happened - Defense World
Scinai Immunotherapeutics Ltd ADR (SCNI) Stock: Uncovering 52-Week Market Trends - investchronicle.com
Scinai Immunotherapeutics (NASDAQ: SCNI) Publishes Peer-Reviewed Data Supporting PC111 as Potential Disease Modifier - Barchart.com
Scinai Immunotherapeutics stock soars on promising skin disease drug data By Investing.com - Investing.com South Africa
Scinai Immunotherapeutics stock soars on promising skin disease drug data - Investing.com Australia
Scinai’s PC111 antibody shows promise for pemphigus treatment By Investing.com - Investing.com Canada
Scinai’s PC111 antibody shows promise for pemphigus treatment - Investing.com India
ICICI Bank Ltd. ADR (IBN) Stock: Navigating a Year of Stock Volatility - investchronicle.com
Scinai Announces New Peer-Reviewed Publication Supporting PC111 as a Disease-Modifying Therapy for Pemphigus and SJS/TEN - Benzinga
Augusta Gold (TSE:G) Shares Pass Below Two Hundred Day Moving Average – Time to Sell? - Defense World
Scinai Immunotherapeutics Faces Financial Challenges, Seeks Growth - TipRanks
Scinai Immunotherapeutics Reports Strong CDMO Growth - TipRanks
Scinai Immunotherapeutics (NASDAQ: SCNI) Expands CDMO Operations with New U.S. Subsidiary - Barchart.com
Scinai Immunotherapeutics (NASDAQ: SCNI) Reports $4.8M Net Gain in 2024, Driven by Loan-to-Equity Conversion - Barchart.com
Scinai Immunotherapeutics (NASDAQ: SCNI) to Host Webinar on PC111 Antibody for Rare Skin Disorders - Barchart.com
Military Breakthrough: BrainChip and Raytheon Land $1.8M Air Force Deal for Next-Gen Radar - Stock Titan
Scinai Immunotherapeutics (NASDAQ: SCNI) Enters Option Agreement to Acquire Italian Biotech Pincell - The Globe and Mail
Bayerische Motoren Werke ADR (OP: BMWYY - FinancialContent
Scinai regains Nasdaq compliance, eyes EIB loan conversion - Investing.com
Scinai Immunotherapeutics enacts reverse split to meet Nasdaq rules - Investing.com
Scinai Immunotherapeutics (NASDAQ: SCNI) Announces Participation at BIO-Europe Munich 2023 - Barchart.com
Scinai Immunotherapeutics Ltd Adr Stock (SCNI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):